
- by sedlv
- December 9 2024
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS
(December 9, 2024) by Dewpoint Therapeutics.
-
- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of >97% of ALS patients.
- Mitsubishi Tanabe Pharma Corporation obtains an option for a global license to develop and commercialize the novel TDP-43 small molecule condensate modulator.
- Deal valued at up to $480 million- Dewpoint to receive upfront and additional development and commercial milestone payments, excluding royalties.